Byetta/Januvia Pancreatic Cancer

Merck and Pfizer teaming up on diabetes drug

A story on HispanicBusiness.com says pharmaceutical companies Merck and Pfizer, ordinarily rivals, are teaming up to develop a new medicine for type 2 diabetes.

Merck is paying $60 million up front for the rights to co-develop Pfizer’s diabetes drug called ertugliflozin, which is currently in late-stage development. Merck will also get the right to market ertugliflozin separately or in combination with its own diabetes treatment.

But recent health concerns have cropped up about ...

continue reading...

Hormone could revolutionize diabetes treatment

According to an NBC News blog, the discovery of a new hormone that makes the cells destroyed by diabetes has enormous potential for treating the disease.

The story says nearly 26 million Americans have diabetes, according to the Centers for Disease Control and Prevention. In both type 1 and some cases of type 2 diabetes, patients have to inject insulin when they eat to make sure the body metabolizes the food properly ...

continue reading...

Byetta manufacturer looking to get bigger share of diabetes market

Drug maker Eli Lilly is increasing its efforts to get a larger share of the diabetes market, Reuters reports.

The story says Lilly is now the fourth-largest diabetes drug manufacturer, with 10.6 percent market share. That puts it behind Denmark’s Novo Nordisk , France’s Sanofi and the U.S.A.’s Merck & Co.

Lilly is looking to change that position, with dozens of medications in development. Among them is the experimental once-weekly injection dulaglutide, for ...

continue reading...

Israeli doctors cautioned about diabetes medication

An article in the Jerusalem Post says the Israeli Health Ministry’s pharmaceutical division is cautioning doctors to be vigilant for cases of pancreatic infections and pancreatic cancer among people taking a class of diabetes drugs that includes Byetta and Januvia.

The story says the announcement followed similar warnings by both the U.S. Food and Drug Administration and its European counterpart about the drugs.

A number of studies have linked both Byetta and Januvia ...

continue reading...

Analysis says diabetes drugs carry risks

Diabetes

A report on FiercePharma says an analysis by safety watchdog group Institute for Safe Medication Practices found the class of diabetes drugs that includes Merck’s Januvia and Bristol-Myers’s Byetta may increase the risk for pancreatitis and pancreatic cancer.

The analysis found that reports of pancreatitis (an inflammation of the pancreas) and pancreatic cancer were about 25 percent higher for the class of drugs known as GLP-1, compared to older treatments.

FiercePharma notes that ...

continue reading...

FDA investigates link betweed diabetes drugs, pancreas disorder

A story posted on the Website of KTRK-TV out of Houston deals with U.S. Food and Drug Administration investigation into a potential link between newer diabetes drugs including Byetta and Januvia, and a potentially dangerous condition called pancreatitis.

According to the story, FDA officials reported that samples of pancreas tissue taken from patients showed inflammation and cellular changes linked with pancreatitis, an inflammation of the pancreas. Alarmingly, pancreatitis has the potential to ...

continue reading...
Page 6 of 13 «...45678...»